
Sign up to save your podcasts
Or


Venrock partner Andrew Gottesdiener speaks with Jigar Raythatha, former CEO of Constellation Pharmaceuticals, about lessons learned from his time at Constellation. As Constellation has evolved from an early-stage company to being acquired by MorphoSys, Raythatha dives into its many life-cycles, his heavy involvement in the recruitment process, and the decision to conduct a PIPE financing. Raythatha also shares the characteristics to look for in an investor syndicate and the challenges of scaling a public company.
By Venrock, a venture capital firm4.8
6262 ratings
Venrock partner Andrew Gottesdiener speaks with Jigar Raythatha, former CEO of Constellation Pharmaceuticals, about lessons learned from his time at Constellation. As Constellation has evolved from an early-stage company to being acquired by MorphoSys, Raythatha dives into its many life-cycles, his heavy involvement in the recruitment process, and the decision to conduct a PIPE financing. Raythatha also shares the characteristics to look for in an investor syndicate and the challenges of scaling a public company.

1,283 Listeners

2,703 Listeners

2,460 Listeners

1,093 Listeners

339 Listeners

323 Listeners

389 Listeners

5,551 Listeners

10,043 Listeners

34 Listeners

531 Listeners

21 Listeners

291 Listeners

473 Listeners

1,424 Listeners